Seeing Is Believing

Currently out of the existing stock ratings of Christopher Raymond, 355 are a BUY (78.54%), 93 are a HOLD (20.58%), 4 are a SELL (0.88%).
Analyst Christopher Raymond, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 49.08% that have a potential upside of 43.9% achieved within 243 days. Previously, Christopher Raymond worked at PIPER SANDLER.
Christopher Raymond’s has documented 983 price targets and ratings displayed on 43 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ABBV, AbbVie at 09-Oct-2025.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 5/31/2018. The price target of $35 was fulfilled within 4 days with a profit of $9.28 (36.08%) receiving and performance score of 90.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$250
$20.43 (8.90%)
$220
7 days ago
(16-Oct-2025)
13/14 (92.86%)
$20.43 (8.90%)
399
Buy
$284
$54.43 (23.71%)
$220
14 days ago
(09-Oct-2025)
43/44 (97.73%)
$53.5 (23.21%)
593
Hold
$251
$21.43 (9.33%)
$205
21 days ago
(02-Oct-2025)
15/16 (93.75%)
$17.09 (7.31%)
300
Buy
$270
$40.43 (17.61%)
$195
1 months 7 days ago
(16-Sep-2025)
2/3 (66.67%)
$49.19 (22.28%)
121
Buy
$235
$5.43 (2.37%)
$200
1 months 8 days ago
(15-Sep-2025)
14/14 (100%)
$18.74 (8.67%)
483
Which stock is Christopher Raymond is most bullish on?
Which stock is Christopher Raymond is most reserved on?
What Year was the first public recommendation made by Christopher Raymond?